Optimistic Buy Rating for Alkermes Based on Promising Narcolepsy Treatment Developments
Robert W. Baird analyst Joel Beatty has maintained their bullish stance on ALKS stock, giving a Buy rating on June 4. Joel Beatty has given ...
bovnews4d
Robert W. Baird Assigned “an Outperform” Rating to Alkermes plc (NASDAQ:ALKS) Stock
Robert W. Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan ...
Buy Rating on Alkermes Based on Promising ALKS-2680 Efficacy in Narcolepsy Type 1 Treatment
Analyst Uy Ear of Mizuho Securities maintained a Buy rating on Alkermes (ALKS – Research Report), retaining the price target of $35.00.
FierceBiotech6d
Alkermes impresses in full-throttle narcolepsy race with Takeda
Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...
The Business Journals6d
Here are Cincinnati's 2024 Business Courier Best Places to Work finalists
The annual Business Courier Best Places to Work program recognizes Greater Cincinnati companies that rate highest for employee satisfaction. Meet the 75 finalists here. The Business Courier has named ...